Technical Analysis for XCUR - Exicure, Inc.

Grade Last Price % Change Price Change
F 1.71 -0.58% -0.01
XCUR closed up 2.99 percent on Wednesday, April 21, 2021, on 42 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 1
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical XCUR trend table...

Date Alert Name Type % Chg
Bullish Engulfing Bullish -0.58%
Wide Bands Range Expansion -0.58%
Oversold Stochastic Weakness -0.58%
Spinning Top Other 2.40%
Lower Bollinger Band Walk Weakness 2.40%
Wide Bands Range Expansion 2.40%
Below Lower BB Weakness 2.40%
Down 3 Days in a Row Weakness 2.40%
Down 4 Days in a Row Weakness 2.40%
Down 5 Days in a Row Weakness 2.40%
Older End-of-Day Signals for XCUR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 1 hour ago
60 Minute Opening Range Breakdown about 2 hours ago
Down 2 % about 2 hours ago
60 Minute Opening Range Breakout about 5 hours ago
Rose Above Previous Day's High about 5 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Exicure, Inc. Description

Exicure, Inc., a clinical-stage biotechnology company, develops gene regulatory and immuno-oncology therapeutics based on spherical nucleic acid (SNA) technology. Its three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA that targets TNF for the treatment of mild to moderate psoriasis. The company has collaboration agreement with Purdue Pharma L.P. Purdue Pharma for the development of AST-005; and license and development agreement DERMELIX, LLC, d/b/a Dermelix Biotherapeutics to research, develop, and commercialize Exicure's technology for the treatment of Netherton Syndrome and for five additional rare skin indications. Exicure, Inc. was founded in 2011 and is headquartered in Skokie, Illinois.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Acid Psoriasis Mild Messenger RNA Oncology Applications Netherton Syndrome Purdue Pharma

Is XCUR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 3.3
52 Week Low 1.38
Average Volume 614,309
200-Day Moving Average 2.03
50-Day Moving Average 2.24
20-Day Moving Average 2.01
10-Day Moving Average 1.86
Average True Range 0.14
ADX 29.09
+DI 11.62
-DI 31.87
Chandelier Exit (Long, 3 ATRs ) 2.22
Chandelier Exit (Short, 3 ATRs ) 2.05
Upper Bollinger Band 2.37
Lower Bollinger Band 1.65
Percent B (%b) 0.1
BandWidth 35.67
MACD Line -0.15
MACD Signal Line -0.11
MACD Histogram -0.0383
Fundamentals Value
Market Cap 150.03 Million
Num Shares 87.2 Million
EPS -0.47
Price-to-Earnings (P/E) Ratio -3.65
Price-to-Sales 8.07
Price-to-Book 1.90
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.87
Resistance 3 (R3) 1.87 1.81 1.85
Resistance 2 (R2) 1.81 1.78 1.82 1.84
Resistance 1 (R1) 1.77 1.75 1.79 1.77 1.83
Pivot Point 1.71 1.71 1.73 1.72 1.71
Support 1 (S1) 1.67 1.68 1.69 1.67 1.61
Support 2 (S2) 1.61 1.65 1.62 1.60
Support 3 (S3) 1.57 1.61 1.60
Support 4 (S4) 1.57